Current Salvage Therapy Options for Relapsed/Refractory CLL
Neil E. Kay, MD, professor of medicine at the Mayo Clinic, addresses the “Big 4” in salvage therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including a newer therapy coming down the pipeline now.
Neil E. Kay, MD, professor of medicine at the Mayo Clinic, addresses the “Big 4” in salvage therapies for patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including a newer therapy coming down the pipeline now.
Based on findings from clinical trials, Kay says the 4 major salvage therapies right now include ibrutinib (Imbruvica), venetoclax (Venclexta), idelalisib(Zydelig)/rituximab (Rituxan), and allogeneic bone marrow transplant. While it remains unclear in which order to administer these treatments, a wise decision can be made based off a patient’s age, comorbidities, and treatment goals.
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
